Abstract: The present invention relates to antibodies targeting Tumor Associated Macrophages (TAMs) and uses thereof. The inventors investigated specific marker exposed on the surface of the macrophages associated to tumor in order to detect and target TAMs. They showed that sideroflexin 3, which is absent in normal macrophage, is expressed by tumor associated macrophages. The inventors further demonstrated that using antibody directed to sideroflexin 3, they depleted TAMs in PBMC sample obtained from LCC patient, and strongly reduced leukemic B cells number.
Type:
Grant
Filed:
July 28, 2017
Date of Patent:
November 30, 2021
Assignees:
INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse, Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse, Institut Claudius Regaud
Inventors:
Mary Poupot, Loïc Ysebaert, Marie Tosolini, Jean-Jacques Fournie, Pierre Brousset, Philippe Rochaix
Abstract: Provided are novel human-derived antibodies specific for transthyretin (TTR), preferably capable of binding misfolded, misassembled, and/or aggregated TTR species, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with TTR amyloidosis are provided. Assays and kits related to antibodies specific for TTR or TTR deposits and aggregates are also disclosed. The novel anti-TTR antibodies can be used in pharmaceutical and diagnostic compositions for TTR targeted immunotherapy and diagnostics.
Abstract: The compositions and methods described herein include methods and agents that inhibit inflammasome signaling in a mammal such as antibodies directed against inflammasome components used alone or in combination with extracellular vesicle uptake inhibitor(s) or other agents. Also described herein are compositions and methods of use thereof for treating viral-associated lung inflammation, for example lung inflammation associated with viral infections such as SARS-CoV-2.
Type:
Grant
Filed:
April 23, 2020
Date of Patent:
November 16, 2021
Assignee:
UNIVERSITY OF MIAMI
Inventors:
Robert W. Keane, W. Dalton Dietrich, Juan Pablo De Rivero Vaccari, Helen M. Bramlett
Abstract: Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin (e.g., botulinum neurotoxin or a fragment thereof, either in pure form or with one or more peptide fragments and/or neurotoxin associated proteins). In some embodiments, the disclosed formulations also include one or more anti-VEGF agents. The disclosed formulations may be applied to an intraocular or extraocular region of a patient.
Abstract: Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin (e.g., botulinum neurotoxin or a fragment thereof, either in pure form or with one or more peptide fragments and/or neurotoxin associated proteins. In some embodiments, the disclosed formulations are applied to the para orbital or periorbital region of a patient to delay or stop the progression of dry macular degeneration. The methods described herein do not involve a direct injection into the eye or subconjunctival region, thus significantly easing both comfort and administration related complications and further preserving barrier functions of retinal layers while also delaying or ceasing the degenerative process to wet conversion.
Abstract: A monoclonal antibody that binds ?-synuclein, and that binds tau fibrils, and methods of using the monoclonal antibody, are provided. The monoclonal antibody may be hybridoma clone 2F11. Also provided is a composition comprising the monoclonal antibody 2F11 and a pharmaceutically acceptable carrier, adjuvant, vehicle or excipient. A method of reducing active ?-synuclein in a subject in need thereof is also disclosed. The method involves administering an amount of the composition comprising 2F11 to the subject. The monoclonal antibody 2F11 may also be used to determine the ?-synuclein, or tau fibril, level in a biological sample.
Abstract: Formulations and methods of treatment are disclosed for prevention and/or treatment of visual loss from age-related macular degeneration. The disclosed formulations include botulinum neurotoxin. The disclosed formulations may be applied to an intraocular or extraocular region of a patient. If applied to an extra ocular region of a patient, the botulinum-based pharmaceutical formulation may then be transported to the intra-ocular region of the patient, allowing the active ingredient(s) to penetrate into the choroid, neuro-retina, and/or retinal pigment epithelium without direct injection into the eye, eliminating risk of retinal detachment, retinal break, retinal hemorrhage, and blindness. The methods described herein allow for increased blood flow to the choroid, which improves removal of metabolites and intra retinal fluid and also serves to arrest, reverse and/or delay early and later stages of age-related macular degeneration.
Abstract: An object of the present invention is to provide a monoclonal antibody that recognizes an extracellular region of Claudin-2. A monoclonal antibody that specifically binds to an extracellular region of Claudin-2.
Type:
Grant
Filed:
December 25, 2017
Date of Patent:
August 3, 2021
Assignee:
Osaka University
Inventors:
Masuo Kondoh, Kiyohito Yagi, Akihiro Watari, Masayoshi Fukasawa, Minoru Tada, Jun Kunisawa
Abstract: An object of the present invention is to provide a novel molecule which has high specificity to CLDN-5 and recognizes an extracellular domain of CLDN-5. The object is achieved by an antibody which specifically recognizes a three-dimensional structure or a primary structure of an extracellular domain of a Claudin-5 protein.
Type:
Grant
Filed:
April 26, 2018
Date of Patent:
July 6, 2021
Assignees:
OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION EHIME UNIVERSITY, FUJIFILM WAKO PURE CHEMICAL CORPORATION
Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
Type:
Grant
Filed:
September 26, 2019
Date of Patent:
June 8, 2021
Assignees:
Prothena Biosciences Limited, University Health Network
Inventors:
Yue Liu, Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
Abstract: The present invention relates to novel nanomaterial-molecular compositions, methods and devices thereof for efficient and targeted trans-differentiation of cells including fibroblasts and glia into neurons, both in vitro as well as in situ and in-vivo, which is of great importance for cell replacement therapies. Specifically, the invention provides a nanomaterial-molecular composition, device and method for targeted nano-enhanced opto-chemical trans-differentiation of fibroblasts/glia to neurons in the central and peripheral nervous system for restoration of neural functions in patients by delivery of nanomaterial-molecular composition, followed by optical illumination.
Abstract: The present specification discloses modified anti-PD-L1 antibodies that abolishes Fc-related effector function and enhances clearance rate while maintaining therapeutic efficacy for neurodegenerative disease modification. The present specification also discloses nucleic acid sequences and expression constructs encoding such modified anti-PD-L1 antibodies as well as methods of making such modified anti-PD-L1 antibodies. In addition, the present specification discloses methods of treatment and uses that employ an administration regime of the disclosed anti-PD-L1 antibodies that ensures the antibodies are present for only a specific period of time and then are sufficiently cleared from the body to ensure treatment efficacy is maintained.
Type:
Grant
Filed:
April 19, 2020
Date of Patent:
May 4, 2021
Assignees:
ImmunoBrain Checkpoint, Inc., Yeda Research and Development Co. Ltd.
Inventors:
Ester Yoles, Berit Olsen Krogh, Allan Jensen, Jan Egebjerg, Carol David, Kuti Baruch, Michal Eisenbach-Schwartz
Abstract: The present invention is based on antibodies which are both highly specific for hyperphosphorylated pathogenic P-S396 tau and highly specific for labelled sections of the human retina, as well as to methods of using these antibodies and their tau binding fragments in the treatment of retinoid amyloidosis, age related macular degeneration (ARMD), and glaucoma.
Type:
Grant
Filed:
January 3, 2018
Date of Patent:
May 4, 2021
Assignee:
H. Lundbeck A/S
Inventors:
Jan Torleif Pedersen, Lars Østergaard Pedersen, Justus Claus Daechsel, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist
Abstract: The present invention relates to compositions and methods for treatment of neurological disorders. In particular, the present invention relates to EGFR as a clinical target for treatment of neurological disorders.
Type:
Grant
Filed:
July 5, 2012
Date of Patent:
April 20, 2021
Assignee:
SYKEHUSET SØRLANDET HF
Inventors:
Christian Kersten, Marte Grønlie Cameron, Svein Mjåland
Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
Type:
Grant
Filed:
March 3, 2020
Date of Patent:
March 30, 2021
Assignee:
PROTHENA BIOSCIENCES LIMITED
Inventors:
Tarlochan S. Nijjar, Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
Abstract: Antibodies to human pituitary adenylate cyclase-activating peptide, compositions comprising such antibodies, and methods of using such antibodies for the treatment of pain including headache and/or migraine.
Type:
Grant
Filed:
November 22, 2019
Date of Patent:
March 23, 2021
Assignee:
Eli Lilly and Company
Inventors:
Chetankumar Natvarlal Patel, Michael Parvin Johnson, Catherine Brautigam Beidler
Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
Type:
Grant
Filed:
November 3, 2014
Date of Patent:
March 16, 2021
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Sabrina Kuttruff-Coqui, Toni Weinschenk, Jens Fritsche, Steffen Walter, Norbert Hilf, Oliver Schoor, Colette Song, Harpreet Singh
Abstract: In alternative embodiments, provided are compositions such as antibodies, e.g., single chain antibodies, that target 3-repeat (3R) Tau for the treatment of neurodegenerative disorders and taupathies such as Alzheimer's Disease (AD), Pick's Disease (PiD) and Fronto-temporal lobar degeneration (FTLD), or any disorder or condition associated with a 3R Tau accumulation, and methods for making and using them. In alternative embodiments, provided are brain-penetrating antibodies that specifically recognize 3R Tau, and methods of using them to treat, ameliorate, prevent or decrease the symptoms of neurodegenerative disorders including taupathies such as Alzheimer's Disease (AD), Pick's Disease (PiD) and Fronto-temporal lobar degeneration (FTLD), or any disorder or condition associated with a 3R Tau accumulation.
Type:
Grant
Filed:
November 3, 2017
Date of Patent:
March 16, 2021
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Eliezer Masliah, Brian Spencer, Edward Rockenstein